Background-Oxidative stress may contribute to the development of heart failure (HF); however, an increased risk of HF has been observed with antioxidant therapy in secondary prevention trials. No large clinical trials have addressed the role of antioxidant therapy in the primary prevention of HF. Methods and Results-We examined the effect of vitamin E and HF risk in 39 815 initially healthy women, aged at least 45 years at baseline, who were enrolled in the Women's Health Study, a randomized, double-blind, placebo-controlled trial of vitamin E (600 IU every other day). Over a median follow-up of 10.2 years, there were 220 incident HF events. In proportional hazards models, adjusting for age and randomized aspirin and beta carotene treatment, vitamin E assignment did not significantly affect HF risk (hazards ratio [HR], 0.93; 95% CI, 0.71-1.21; Pϭ0.59). These results did not change with multivariate adjustment for other risk factors, including interim myocardial infarction. In a prespecified subgroup analysis, vitamin E was inversely related to developing HF with normal ejection fraction (Ն50%) with HR 0.59 (95% CI, 0.38-0.92; Pϭ0.02), but there was no statistically significant effect on the risk of developing systolic HF (HR, 1.26; 95% CI, 0.84-1.89; Pϭ0.26). Conclusions-In this population of apparently healthy women, vitamin E did not affect the overall risk of HF. The possible benefit on diastolic HF requires confirmation in larger populations. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00000479. (Circ Heart Fail. 2012;5:176-182.) 
H eart failure (HF) is a leading cause of cardiovascular morbidity and mortality, constituting a substantial and costly public health burden. More than 5.7 million people in the United States have HF, with 670 000 new cases diagnosed per year. 1 The prevalence and incidence of HF will continue to rise because of aging of the population, as well as increasing survival with associated risk factors such as hypertension and coronary artery disease. Furthermore, despite advances in therapy, prognosis remains poor, with 50% of patients with HF dying within 5 years of diagnosis. 1 Therefore, identification of therapeutic interventions and modifiable lifestyle factors that may aid in the primary prevention of HF is of critical importance. 2 
Clinical Perspective on p 182
Antioxidant therapy has been identified as a promising intervention that may reduce the risk of HF, based on experimental data showing that oxidative stress may play an important role in HF pathophysiology 3, 4 and that this risk may be ameliorated by antioxidant therapies. [5] [6] [7] [8] [9] Despite these promising biological data, long-term treatment with vitamin E was associated with an increased risk of HF and hospitalization for HF among patients with vascular disease or diabetes enrolled in the Heart Outcomes Prevention Evaluation [HOPE] trial. 10 A similar, albeit nonsignificant, elevation in HF risk was also observed in patients with recent myocardial infarction enrolled in the GISSI-Prevenzione trial. In addition, vitamin E was associated with a significant 50% increase in HF risk in patients with left ventricular ejection fraction (LVEF) Ͻ50% at baseline. 11 No study, however, has examined whether vitamin E influences the risk of HF in a primary prevention population, particularly among women where a lower proportion of HF is due to systolic dysfunction. [12] [13] [14] [15] In addition, it is unclear whether vitamin E has a differential effect on HF risk, depending on the underlying primary pathophysiology of systolic or diastolic HF. To address these questions, we examined the overall effect of long-term vitamin E treatment on HF risk in the Women's Health Study (WHS), a large-scale randomized clinical trial of vitamin E among apparently healthy women. 16 We then examined whether the relationship between vitamin E and HF differed based on the presence or absence of diminished systolic function, defined as an LVEF Ͻ50%.
Methods

Study Design and Sample
Study subjects were participants of WHS (a randomized, doubleblind, placebo-controlled, 2ϫ2 factorial trial), which examined the benefits and risks of low-dose aspirin and vitamin E in the primary prevention of cardiovascular disease and cancer and was completed on March 31, 2004 . Beginning in 1993, 39 876 female health professionals in the United States, who were at least 45 years of age and free of CVD and cancer, were randomly assigned to receive aspirin (100 mg every other day), vitamin E (600 IU every other day), both agents, or placebo. A third arm of the trial, which tested beta carotene, was terminated early in January 1996 because of other trials of beta carotene that had null results or suggested possible harm among those at high risk for lung cancer. 17 All participants provided written, informed consent. The institutional review board of Brigham and Women's Hospital, Boston, approved the study, and an external data and safety monitoring board monitored the study.
Details of the study design have been described previously. 18, 19 In brief, study participants received calendar packs containing active agents or placebo each year. Every 6 months for the first year and annually thereafter, study participants received follow-up questionnaires that inquired about compliance with study medications, adverse effects, risk factors, and occurrence of end points. Compliance, defined as taking at least two thirds of the study capsules, averaged 75.8% and was similar between the active treatment and placebo groups. 16 Use of nontrial vitamin E supplements for at least 4 days per month was lower in the active treatment group than in the placebo group (8.5% versus 8.9%, Pϭ0.07). 16 Morbidity and mortality follow-up were 97.2% and 99.4% complete, respectively. 16 The primary results for cardiovascular disease and cancer have been published previously. 16, 20 For the purposes of this analysis, we excluded 13 women who had prevalent cardiovascular disease (but reported after women had already been randomized into the WHS) and 48 who had evidence of HF before randomization, resulting in a study cohort of 39 815 women.
Study Variables and End Point Ascertainment
Covariates of interest were self-reported on the baseline questionnaire and included age; race/ethnicity (which was self-reported by participants as white, black, Hispanic American, Asian American, or other); blood pressure; height and weight; history of hypertension, diabetes, and hypercholesterolemia; lifestyle habits, including smoking status, alcohol use, and physical activity; menopausal status and current use of hormone therapy; and multivitamin use.
Women reported the occurrence of nonfatal end points via annual follow-up questionnaires, letters, or telephone calls. Family members or postal authorities reported deaths, or deaths were ascertained via the National Death Index. After obtaining written consent, medical records were obtained and adjudicated, according to predefined criteria, by an end point committee of physicians blinded to treatment assignment. Myocardial infarction was confirmed if symptoms met World Health Organization criteria and if the event was associated with abnormal levels of cardiac enzymes or diagnostic electrocardiograms. 19
Validation of Incident HF
On the 48-month questionnaire, study participants were asked to report any prior physician diagnosis of HF, along with the month and year of diagnosis. On annual questionnaires thereafter, they were asked to report diagnoses of incident HF. Women who reported the diagnosis of HF received a supplemental questionnaire to provide additional information regarding symptoms, diagnostic evaluation, current medical therapy, and functional status and to grant permission to obtain and review their relevant medical records, including physician and hospital records, laboratory and chest x-ray data, and results of diagnostic tests, including electrocardiograms, echocardiograms, stress tests, and cardiac catheterizations. If the diagnosis of HF was mentioned in medical records obtained for the purpose of confirming other end points, these records were also reviewed. For deceased participants, we contacted family members to obtain consent for medical records pertaining to the diagnosis of HF.
Cardiologists blinded to treatment assignment reviewed the medical records and confirmed a diagnosis of HF according to predefined criteria. Cases of incident nonfatal HF were confirmed if either the Framingham Heart Study 21 or Cardiovascular Health Study 22 criteria were met. The Framingham Heart Study criteria rely on physical examination findings and radiographic data ( Table 1) , while the Cardiovascular Health Study criteria are predominantly based on the treating physician's diagnosis of HF and use of specific medical therapy for HF (diuretic and digitalis or a vasodilator). "Definite" cases of nonfatal HF met both Framingham Heart Study and Cardiovascular Health Study criteria, and "probable" cases of nonfatal HF met either Framingham Heart Study or Cardiovascular Health Study criteria, but not both. 23, 24 Fatal HF cases included those not identified as a case of HF prior to death (Nϭ2). "Definite" fatal HF was defined as meeting any of the following criteria from medical record review: pulmonary edema, visceral congestion, cardiomegaly on autopsy 21 ; death due to shock or low output syndrome 22 ; The International Classification of Diseases, Ninth Revision, code 428.xx or 425.xx on the death certificate with next-of-kin or physician confirmation of HF as the immediate or underlying cause of death; or history of severe chronic HF, with the primary cause of death due to a related cause such as a ventricular arrhythmia. 25 "Probable" fatal HF was defined as HF as the immediate or underlying cause of death on the death certificate, in the absence of available records or data fulfilling criteria for definite fatal HF. 26 Information on left ventricular ejection fraction (LVEF) within 3 months of the diagnosis of incident HF was collected from medical record review and based on diagnostic tests performed closest to the date of diagnosis of incident HF. The mean duration between testing and incident HF diagnosis was 8.3 (15. 3) days, with 90% being performed within 1 month of the diagnosis. The majority of the ejection fraction data were derived from echocardiography (68.8%) or left ventriculography (25.0%). Data were collected primarily as continuous variables, and, if the report described ejection fraction as a range, the midpoint value was used. If the degree of impairment of 
Pleural effusion by chest x-ray
Pulmonary vascular engorgement on chest x-ray *Heart failure was confirmed if participant had 2 major criteria or 1 major plus 2 minor criteria.
HF indicates heart failure.
systolic function was described qualitatively, we classified "none" or "mild" left ventricular dysfunction as having LVEF Ն50% and "moderate" or "severe" systolic dysfunction as having LVEF Ͻ50%. We defined systolic HF as incident HF occurring in the setting of LVEF Ͻ50% and HF with normal ejection fraction (or "diastolic" HF) as incident HF occurring in the setting of LVEF Ն50%. 27, 28 For this analysis, the primary end point was all incident HF, which included both definite and probable cases of nonfatal and fatal HF. 23, 24 We also performed sensitivity analyses, confining the end point to cases of definite HF. To examine whether the relationship between vitamin E and HF varied depending on left ventricular function, we performed prespecified analyses using the end points of systolic or diastolic HF. Follow-up was censored at the end of the trial.
Statistical Analysis
All analyses were performed on an intention-to-treat basis. Personyears of follow-up were calculated from baseline to the date of the incident HF event, death, or the end of the trial, whichever came first. Kaplan-Meier curves were constructed to estimate the cumulative incidence of HF by randomized treatment group. The log rank test was used to compare incidence rates. Proportional hazards models were constructed to calculate the hazards ratios (HR) and 95% confidence intervals (CI) for vitamin E assignment compared with placebo and the risk of incident HF, adjusted for age and randomized aspirin and beta carotene assignment. These models were further adjusted for race/ethnicity, hypertension (defined as a self-reported history of hypertension, or systolic blood pressure 140 mm Hg or higher, or diastolic blood pressure 90 mm Hg or higher), hypercholesterolemia (defined as being on lipid-lowering therapy or having a total cholesterol of 240 mg/dL or greater), diabetes, body mass index (calculated as weight in kilograms divided by height in meters 2 ), smoking status, alcohol use, physical activity, menopausal status and current hormone therapy use, and multivitamin use. For the sensitivity analyses confining the end point to cases of definite nonfatal and fatal HF, participants with probable HF were censored at the time of their HF diagnosis. The proportional hazards assumption was examined by including an interaction term of vitamin E with the logarithm of time in the Cox models for the end point of HF and was not violated.
To examine if there was a differential effect of vitamin E on HF risk by left ventricular function, we performed a prespecified series of proportional hazards models using systolic HF and HF with normal ejection fraction as the outcomes. For the end point of systolic HF, participants with diastolic HF were censored at the time of their HF diagnosis, and vice versa.
We also performed several additional exploratory analyses. To evaluate whether the association between vitamin E and HF risk was mediated by coronary artery disease, we constructed another series of multivariate models that additionally controlled for interim myocardial infarction as a time-varying covariate. Effect modification of the association between vitamin E assignment and HF risk was examined using stratified analyses and testing for interaction, by means of multiplicative interaction terms for vitamin E and relevant baseline characteristics, incorporating likelihood ratio tests, and testing for trend when subgroup categories were ordinal.
All analyses were performed using SAS version 9 (SAS Institute Inc). A 2-tailed PϽ0.05 was considered statistically significant.
Results
The 39 815 women in the study cohort had a mean age at randomization of 54.6 (7.04) years. Clinical characteristics were balanced and are described in Table 2 . Over median follow-up of 10.23 years, there were 220 incident HF events. Of these, 106 had been randomized to vitamin E, and 114 had been randomized to placebo. As shown in the Figure, there was no significant overall difference in the cumulative incidence of HF over the duration of follow-up between the vitamin E and placebo groups (log rank Pϭ0.59). In propor-tional hazard models, adjusting for age and randomized aspirin and beta carotene assignment, vitamin E assignment remained unassociated with HF risk (HR, 0.93; 95% CI, 0.71-1.21; Pϭ0.59). These results did not substantially change after multivariate adjustment for other clinically relevant covariates and potential confounders and were unaffected by additional control for interim myocardial infarction (Table 3 ). When these analyses were repeated in sensitivity analyses limited to definite HF cases (nϭ158, 72%), the results were similar. Compared with placebo, vitamin E assignment was associated with HR, 0.90 (95% CI, 0.66 -1.23; Pϭ0.50) for definite HF after full multivariate adjustment, including for interim myocardial infarction.
Among the 220 HF events, ejection fraction data were available in 176 participants (80%). Of these, 95 participants (54%) had LVEF Ͻ50% while 81 participants (46%) had LVEF Ն50% around the time of HF diagnosis. As shown in Table 3 , vitamin E assignment did not affect the risk of systolic HF in this population of healthy women; however, vitamin E assignment resulted in a significant 40% reduction in the risk of developing HF in the setting of normal ejection fraction (Pϭ0.02). This risk estimate remained essentially unchanged after multivariate adjustment. We also explored our data for potential effect modification of the association between vitamin E and HF by important clinical characteristics. As shown in Table 4 , there was the suggestion of effect modification by postmenopausal status and hormone use (P for interaction 0.02), as well as by multivitamin use (P for interaction 0.04). There was no evidence of effect modification by randomization to aspirin or ␤-carotene; age; race/ethnicity; history of other medical conditions such as diabetes, hypertension, or hypercholesterolemia; body mass index; smoking status; alcohol intake; or physical activity level.
Discussion
In this large randomized clinical trial, vitamin E assignment had no association with the risk of incident HF in initially healthy women; however, although vitamin E did not influence the risk of developing systolic HF, it was associated with a significant 40% reduction in the risk of developing HF with normal ejection fraction. To the best of our knowledge, these are the only data available regarding the influence of vitamin E on HF risk in a primary prevention population.
Our findings differ somewhat from prior data from secondary prevention trials that raised concern about vitamin E Similar increases in HF risk were seen in the 7040 participants followed for an additional 2.6 years in the HOPE-TOO extension trial. In GISSI-Prevenzione, 11 an open label trial of vitamin E (300 mg/d) without placebo control, 8415 patients (mean age, 58.4 years; 13.9% women), who had a myocardial infarction in the prior 3 months, were followed for 3.5 years for the development of HF, defined as the need of hospitalization for HF management or death from HF, as classified by an end point validation committee. Similar to HOPE, vitamin E was associated with a 20% increased risk of HF (RR, 1.20; 95% CI, 0.92-1.56; Pϭ0.18), although this was not statistically significant. When stratified by tertiles of ejection fraction at baseline, patients with LVEF Ͻ50% had a significantly increased risk of HF with vitamin E compared with controls who did not receive vitamin E (RR, 1.50; 95% CI, 1.03-2.20; Pϭ0.0345). Potential explanations for the contrast between our findings and those of the HOPE and GISSI-Prevenzione trials include differences in the populations studied. Perhaps most importantly, WHS was a primary prevention trial that examined the effect of vitamin E in a cohort of apparently healthy individuals, whereas HOPE and GISSI-Prevenzione were secondary prevention trials, conducted in patients with preexisting vascular disease or its equivalent, or prior myocardial infarction, respectively. In addition, we could not exclude differences in the effect of vitamin E based on sex. In contrast to WHS, the HOPE and GISSI trials involved relatively small populations of women (26.7% and 13.9%, respectively), although the HOPE investigators reported no differences in subgroup analysis by sex. The doses and dosing regimens of vitamin E differed among these trials, with WHS testing a dose of 600 IU on alternate days, whereas HOPE and GISSI-Prevenzione used doses of 400 IU daily and 300 mg daily, respectively. Finally, the incidence of HF in our cohort was lower than in HOPE and GISSI-Prevenzione, which is not unexpected, given that WHS is a younger, primary prevention population; however, the smaller number of end points may have limited our statistical power to detect an association between vitamin E and HF risk. Based on our confidence intervals (95% CI, 0.71-1.21), we cannot rule out a modest effect of vitamin E on HF risk (ie, up to a 29% reduction or a 21% increase in risk, the latter of which would be similar in direction and degree to the HOPE and GISSI-Prevenzione findings).
Although we observed an overall null effect of vitamin E on HF risk, in a prespecified subgroup analysis, we found a protective effect of vitamin E assignment on the risk of developing HF with normal ejection fraction. This finding should be interpreted with caution, since it was a subgroup analysis based on a relatively small number of HF cases, but it nevertheless merits further study. HF with normal ejection fraction, where the primary abnormality is related to diastolic dysfunction or impaired relaxation, represents approximately half of all cases of HF. [12] [13] [14] [15] [27] [28] [29] Diastolic HF is increasing in prevalence and is more common in women than in men. [12] [13] [14] [15] 29 Although associated with similar biological derangements and adverse prognosis as systolic HF, [12] [13] [14] [15] [27] [28] [29] fewer effective therapies exist. Recent studies in animals have demonstrated that oxidative stress may play an important role in diastolic dysfunction and that antioxidant therapies may improve diastolic performance in conditions including hypertension, insulin resistance and diabetes, and hypercholesterolemia. 30 -34 Strengths of this study include the fact that WHS was a large, prospective, randomized clinical trial of vitamin E, with long duration of follow-up. In addition, the incident cases of HF were validated using established epidemiological criteria. Our study also has several limitations. Because WHS participants were healthy, middle-aged, and predominantly Caucasian female health professionals, our findings may not be generalizable to other populations. The incidence rate of HF in WHS (0.56 per 1000 person-years) is lower than typically reported in other epidemiological studies, although limited data exist on HF incidence in younger populations such as WHS. For example, in the community-based Atherosclerosis Risk In Communities (ARIC) study, the HF incidence rate in Caucasian women was 3.4 per 1000 person years, adjusted to the mean age at baseline of 54 years. 35 The lower incidence rate of HF in WHS may be explained by the substantially lower rates of risk factors such as hypertension, diabetes, smoking, and obesity in WHS compared with ARIC; in addition, in ARIC, participants with prevalent coronary heart disease at baseline were not excluded from their analysis. An additional limitation is that we could not assess if vitamin E has a differential effect on HF risk in women with or without valvular heart disease, as there were only 15 cases for whom severe valvular disease could be determined to be the primary etiology. We did not otherwise attempt to assign a primary etiology to the HF cases in WHS because of the frequent coexistence of causes of HF (eg, coronary artery disease, hypertension, and diabetes), as well as clinical variability in the use of diagnostic testing such as coronary angiography. Ejection fraction data were derived from medical record review of tests performed in the clinical setting, as opposed to assessment by a standardized protocol, which may result in variability in these measurements. HF events were self-reported by WHS participants; however, the confirmation rate in WHS was 67%, comparable to those in other epidemiological studies, 36, 37 and the reports were validated by application of standardized epidemiological criteria. Our findings apply only to vitamin E in the formulation and dose-tested in WHS and cannot be generalized to other antioxidant therapies. Finally, although this is the largest study of vitamin E and HF risk in a primary prevention population, owing to the limited number of events, we cannot completely exclude a small to moderate effect of vitamin E on HF risk based on these data.
In conclusion, long-term treatment with vitamin E did not affect the overall risk of incident HF in this randomized trial of initially healthy women. These results underscore the importance of focusing on other primary prevention measures proven to reduce the risk of future HF, including effective control of blood pressure and the primary prevention of coronary artery disease. 2 If the inverse association between vitamin E and diastolic HF is confirmed in other prospective studies, then future randomized trials of antioxidant therapy in patient populations at high risk for diastolic HF may be warranted; however, at the present time, the cumulative evidence to date does not support the use of vitamin E supplementation to reduce the risk of cardiovascular diseases.
